×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
Zacks Investment Research
In the latest trading session, Intellia Therapeutics, Inc. (NTLA) closed at $23.60, marking a +1.42% move from the previous day.
8 hours ago
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
Yahoo Finance
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company...
1 day ago
Intellia, Aera the latest gene editing biotechs to lay off staff
Fierce Biotech
Intellia Therapeutics is the latest gene editing biotech to downsize following a dismal year for the industry.
3 months ago
Intellia Therapeutics doses first patient in pivotal in vivo CRISPR trial
Clinical Trials Arena
Intellia Therapeutic's NTLA-2001 is the first in vivo CRISPR candidate to make late-stage trials.
1 month ago
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary ...
ConchoValleyHomepage.com
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be...
4 days ago
Intellia Therapeutics Ends Co-Development Agreement With Regeneron
Morningstar
Intellia Therapeutics Ends Co-Development Agreement With Regeneron ... Intellia Therapeutics said in a filing that it has notified Regeneron...
1 month ago
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 3.8% decline adds to one-year losses, institutional investors may consider drastic measures
Simply Wall Street
Key Insights Significantly high institutional ownership implies Intellia Therapeutics' stock price is sensitive to...
5 days ago
Better Cathie Wood Stock: Moderna vs. Intellia
The Motley Fool
The idea is to buy promising companies for a good price and hold onto the shares for a number of years -- giving those companies time to bring...
1 month ago
Intellia propels into 2024 with CRISPR pipeline updates
Pharmaceutical Technology
The Massachusetts-headquartered company announced its 2024 aim to complete patient enrolment for studies evaluating NTLA-2001 and NTLA-2002.
3 months ago
Intellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursday
MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.
13 hours ago